Adzick NS, De Leon DD, States LJ, Lord K, Bhatti TR, Becker SA, Stanley CA. Surgical treatment of congenital hyperinsulinism: Results from 500 pancreatectomies in neonates and children. J Pediatr Surg. 2019 Jan;54(1):27-32. doi: 10.1016/j.jpedsurg.2018.10.030. Epub 2018 Oct 5.
Lord K, Radcliffe J, Gallagher P, Adzick NS, Stanley CA, De León DD: High Risk of Diabetes and Neurobehavioral Deficits in Individuals with Surgically Treated Hyperinsulinism J Clin Endocrinol Metab 100(11): 4133-4139, November 2015.
Lord K, Dzata E, Snider KE, Gallagher PR, De León DD. Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases. J Clin Endocrinol Metab. 2013 Sep 20. [Epub ahead of print]
Lord K, De León DD. Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management. Int J Pediatr Endocrinol. 2013 Feb 6;2013(1):3.
Stanescu DE, Lord K, Lipman TH. The epidemiology of type 1 diabetes in children. Endocrinol Metab Clin North Am. 2012 Dec;41(4):679-94.
Lord K, De Leon DD: Hyperinsulinism. The 5-Minute Pediatric Consult, 7th Edition 2015.
Lord K and Rossi W.: Acquired Hypothyroidism. Decision Support in Medicine 2014.
Posters and Presentations
Lord K, Stewart N, Langdon D, De León DD. Lanreotide is a Safe and Effective Treatment for Congenital Hyperinsulinism. 10th International Joint Meeting of Pediatric Endocrinology, Washington DC September 2017.
Vajravelu ME, Lord K, Givler S, De Leon DD: Protein-induced Hypoglycemia in KATP Hyperinsulinism is Mediated by the GLP-1 Receptor. Eastern Society of Pediatric Research, Philadelphia PA March 2016
Patient Experience Ratings
About the Patient Experience Rating System
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.